A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab

Antibodies (mAbs) and antibody fragments (Fabs) constitute one of the largest and most rapidly expanding groups of protein pharmaceuticals. In particular, antibody fragments have certain advantages over mAbs in some therapeutic settings. However, due to their greater chemical diversity, they are mor...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ozge Tatli, Yagmur Oz, Baran Dingiloglu, Duygu Yalcinkaya, Ezgi Basturk, Melis Korkmaz, Latif Akbulut, Derya Hatipoglu, Cansin Kirmacoglu, Buse Akgun, Kubra Turk, Orkun Pinar, Berna Sariyar Akbulut, Zeynep Atabay, Eda Tahir Turanli, Dilek Kazan, Gizem Dinler Doganay
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2023-11-01
Serie:	Heliyon
Soggetti:	Antibody fragment Pharmaceutical purification Biosimilar production Liquid chromatography Mass spectrometry
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2405844023082099
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!